U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
Go back to U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children| Pfizer Inc. (NYSE: PFE) | Delayed: 27.49 -0.15 (0.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.64 | 52 Week High | $37.39 | |||
| Open | $27.64 | 52 Week Low | $28.25 | |||
| Day High | $27.66 | P/E | 16.66 | |||
| Day Low | $27.34 | EPS | $1.65 | |||
| Volume | 9,296,329 | |||||
